HRP20180709T1 - Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona - Google Patents
Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinonaInfo
- Publication number
- HRP20180709T1 HRP20180709T1 HRP20180709TT HRP20180709T HRP20180709T1 HR P20180709 T1 HRP20180709 T1 HR P20180709T1 HR P20180709T T HRP20180709T T HR P20180709TT HR P20180709 T HRP20180709 T HR P20180709T HR P20180709 T1 HRP20180709 T1 HR P20180709T1
- Authority
- HR
- Croatia
- Prior art keywords
- indolinon
- capsula
- derivatives
- dosage form
- pharmaceutical dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08157748 | 2008-06-06 | ||
| PCT/EP2009/056878 WO2009147212A1 (en) | 2008-06-06 | 2009-06-04 | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
| EP09757593.0A EP2299987B1 (en) | 2008-06-06 | 2009-06-04 | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180709T1 true HRP20180709T1 (hr) | 2018-06-15 |
Family
ID=40911908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180709TT HRP20180709T1 (hr) | 2008-06-06 | 2009-06-04 | Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona |
Country Status (35)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA107560C2 (uk) * | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| US20170065529A1 (en) | 2015-09-09 | 2017-03-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical dosage form for immediate release of an indolinone derivative |
| NO2299987T3 (enExample) | 2008-06-06 | 2018-07-21 | ||
| WO2011151087A1 (en) * | 2010-06-02 | 2011-12-08 | Astellas Deutschland Gmbh | Oral dosage forms of bendamustine |
| JO3659B1 (ar) * | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| GB201020032D0 (en) * | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| JP2015532272A (ja) | 2012-09-28 | 2015-11-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ |
| US20140350022A1 (en) | 2013-05-10 | 2014-11-27 | Boehringer Ingelheim International Gmbh | Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment |
| US20150044288A1 (en) | 2013-07-31 | 2015-02-12 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
| US20150209360A1 (en) * | 2014-01-30 | 2015-07-30 | Orbz, Llc | Oral caffeine delivery composition |
| CN106031716B (zh) * | 2015-03-13 | 2022-04-15 | 江苏豪森药业集团有限公司 | 含有吲哚满酮衍生物混悬液的药物制剂及其制备方法 |
| WO2016200688A1 (en) | 2015-06-06 | 2016-12-15 | Cloudbreak Therapeutics, Llc | Compositions and methods for treating pterygium |
| CN107019697A (zh) * | 2016-02-02 | 2017-08-08 | 瑞阳(苏州)生物科技有限公司 | 预防或治疗纤维化疾病的药物组合物及其应用 |
| KR102408596B1 (ko) | 2016-06-02 | 2022-06-13 | 에이디에스 테라퓨틱스 엘엘씨 | 비정상적 신생혈관이 있는 안구 질환 치료를 위한, 닌테다닙을 사용하는 조성물 및 방법 |
| WO2018080795A1 (en) * | 2016-10-25 | 2018-05-03 | Glykon Technologies Group, Llc | Hydroxycitric acid compounds and capsule liquid delivery |
| CN108066343A (zh) * | 2016-11-08 | 2018-05-25 | 瑞阳(苏州)生物科技有限公司 | 一种预防或治疗肾纤维化疾病的药物 |
| JP2019536812A (ja) | 2016-12-12 | 2019-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ |
| JP2020512364A (ja) | 2017-03-28 | 2020-04-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 筋ジストロフィーの処置方法において使用するためのニンテダニブ |
| CN107184549B (zh) * | 2017-04-11 | 2020-11-20 | 江苏大学 | 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法 |
| RS67241B1 (sr) | 2017-10-23 | 2025-10-31 | Boehringer Ingelheim Int | Nova kombinacija aktivnih agensa za lečenje progresivnih fibroznih intersticijalnih bolesti pluća (pf-ild) |
| WO2019106692A1 (en) * | 2017-11-29 | 2019-06-06 | Sun Pharmaceutical Industries Limited | Oral suspension of nintedanib esylate |
| PE20201502A1 (es) | 2018-03-07 | 2020-12-29 | Pliant Therapeutics Inc | Compuestos de aminoacidos y metodos de uso |
| EP3806858A4 (en) | 2018-06-15 | 2022-03-09 | Handa Pharmaceuticals, Inc. | KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF |
| WO2020053665A2 (en) * | 2018-09-13 | 2020-03-19 | Ftf Pharma Private Limited | Non-aqueous chemotherapeutic suspensions for oral dosage |
| US20210346302A1 (en) * | 2018-10-15 | 2021-11-11 | Cipla Limited | Pharmaceutical Formulation |
| CN112386580B (zh) * | 2019-08-13 | 2022-07-08 | 齐鲁制药有限公司 | 具有改善的溶出度和稳定性的尼达尼布药物制剂、制备方法及其应用 |
| EP4069227A1 (en) | 2019-12-04 | 2022-10-12 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
| CN115361950A (zh) | 2020-04-01 | 2022-11-18 | 勃林格殷格翰国际有限公司 | 生物标记物在治疗纤维化病症中的用途 |
| EP4098246A1 (en) | 2021-05-31 | 2022-12-07 | Lotus Pharmaceutical Co., Ltd. | Formulation of nintedanib |
| JP2024539645A (ja) * | 2021-10-14 | 2024-10-29 | プライアント・セラピューティクス・インコーポレイテッド | インテグリン阻害剤及び他の薬剤と組み合わせたその使用 |
| CN114404382B (zh) * | 2022-01-24 | 2023-05-12 | 南京康川济医药科技有限公司 | 乙磺酸尼达尼布软胶囊及其制备方法 |
| EP4486326A1 (en) | 2022-02-28 | 2025-01-08 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
| JP2025525881A (ja) | 2022-08-16 | 2025-08-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼内使用するためのニンテダニブの医薬製剤 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2870062A (en) | 1956-04-27 | 1959-01-20 | Scherer Corp R P | Gelatin composition for capsules |
| GB8305693D0 (en) | 1983-03-02 | 1983-04-07 | Scherer Ltd R P | Pharmaceutical compositions |
| EP0169398B1 (de) | 1984-07-24 | 1990-08-29 | R.P. Scherer GmbH | Oxytetracyclin-HC1-Weichgelatinekapseln und Verfahren zu ihrer Herstellung |
| GB9313329D0 (en) * | 1993-06-28 | 1993-08-11 | Scherer Ltd R P | Softgel capsule shell compositions |
| DE19603402A1 (de) | 1995-02-24 | 1996-08-29 | Basf Ag | Weichgelatinekapseln |
| US6762180B1 (en) | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
| CZ20032959A3 (cs) * | 2001-05-01 | 2004-01-14 | Pfizer Products Inc. | Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva |
| DE10233500A1 (de) * | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| US20060293260A1 (en) * | 2005-05-24 | 2006-12-28 | Wyeth | Useful high load concentrate compositions for control of ecto-and endo-parasites |
| SI1948180T1 (sl) | 2005-11-11 | 2013-06-28 | Boehringer Ingelheim International Gmbh | Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje |
| NO2299987T3 (enExample) | 2008-06-06 | 2018-07-21 | ||
| EP2985025B1 (en) | 2008-06-06 | 2018-01-17 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination |
| UA107560C2 (uk) * | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| WO2010081817A1 (en) * | 2009-01-14 | 2010-07-22 | Boehringer Ingelheim International Gmbh | Method for treating colorectal cancer |
| US8802384B2 (en) | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
| EP2429520A1 (en) | 2009-05-14 | 2012-03-21 | Boehringer Ingelheim International GmbH | New combination therapy in treatment of oncological and fibrotic diseases |
-
2009
- 2009-06-04 NO NO09757593A patent/NO2299987T3/no unknown
- 2009-06-04 LT LTEP09757593.0T patent/LT2299987T/lt unknown
- 2009-06-04 HU HUE09757593A patent/HUE039187T2/hu unknown
- 2009-06-04 SI SI200931833T patent/SI2299987T1/en unknown
- 2009-06-04 ES ES09757593.0T patent/ES2669469T3/es active Active
- 2009-06-04 BR BRPI0913434A patent/BRPI0913434B8/pt active IP Right Grant
- 2009-06-04 WO PCT/EP2009/056878 patent/WO2009147212A1/en not_active Ceased
- 2009-06-04 KR KR1020177004310A patent/KR20170020557A/ko not_active Withdrawn
- 2009-06-04 MX MX2014006908A patent/MX359229B/es unknown
- 2009-06-04 CA CA2726267A patent/CA2726267C/en active Active
- 2009-06-04 UA UAA201100098A patent/UA104590C2/ru unknown
- 2009-06-04 JP JP2011512128A patent/JP5661031B2/ja active Active
- 2009-06-04 CN CN200980121067.8A patent/CN102056598B/zh not_active Ceased
- 2009-06-04 EA EA201001856A patent/EA029996B1/ru not_active IP Right Cessation
- 2009-06-04 EP EP09757593.0A patent/EP2299987B1/en active Active
- 2009-06-04 PE PE2009000782A patent/PE20100254A1/es not_active Application Discontinuation
- 2009-06-04 NZ NZ60316209A patent/NZ603162A/en unknown
- 2009-06-04 HR HRP20180709TT patent/HRP20180709T1/hr unknown
- 2009-06-04 KR KR1020107027317A patent/KR101725469B1/ko active Active
- 2009-06-04 PL PL09757593T patent/PL2299987T3/pl unknown
- 2009-06-04 DK DK09757593.0T patent/DK2299987T3/en active
- 2009-06-04 MY MYPI2010005645A patent/MY158930A/en unknown
- 2009-06-04 AU AU2009254548A patent/AU2009254548B2/en active Active
- 2009-06-04 PT PT97575930T patent/PT2299987T/pt unknown
- 2009-06-04 US US12/995,869 patent/US20110301177A1/en not_active Abandoned
- 2009-06-04 MX MX2010013203A patent/MX2010013203A/es active IP Right Grant
- 2009-06-04 CN CN201510660732.8A patent/CN105193720B/zh not_active Ceased
- 2009-06-04 RS RS20180491A patent/RS57142B1/sr unknown
- 2009-06-05 AR ARP090102039A patent/AR072059A1/es unknown
- 2009-06-05 TW TW098118825A patent/TW201002691A/zh unknown
- 2009-06-08 UY UY0001031879A patent/UY31879A/es not_active Application Discontinuation
-
2010
- 2010-10-26 ZA ZA2010/07636A patent/ZA201007636B/en unknown
- 2010-10-26 IL IL208954A patent/IL208954A/en active IP Right Grant
- 2010-11-22 CL CL2010001279A patent/CL2010001279A1/es unknown
- 2010-12-03 CO CO10152519A patent/CO6280467A2/es not_active Application Discontinuation
- 2010-12-03 EC EC2010010660A patent/ECSP10010660A/es unknown
- 2010-12-06 MA MA33402A patent/MA32385B1/fr unknown
-
2013
- 2013-08-30 US US14/015,186 patent/US20140004187A1/en not_active Abandoned
-
2014
- 2014-08-11 JP JP2014163667A patent/JP5905542B2/ja active Active
-
2015
- 2015-10-07 US US14/877,132 patent/US20160022672A1/en not_active Abandoned
-
2016
- 2016-07-07 US US15/204,277 patent/US9907756B2/en active Active
-
2018
- 2018-05-15 CY CY20181100499T patent/CY1120533T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180709T1 (hr) | Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona | |
| CY2018030I1 (el) | Φαρμακοτεχνικη μορφη 514 | |
| HUE053357T2 (hu) | Gyógyszerészeti készítmény és annak beadásai | |
| EP2381773A4 (en) | COMPOSITIONS FOR DRUG DELIVERY | |
| DK2632493T3 (da) | Lægemiddelindgivelsessammensætninger | |
| BRPI1009324A2 (pt) | compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos | |
| IL230786A0 (en) | Heterocyclic derivative and pharmaceutical drug | |
| HUE040307T2 (hu) | Új oxintomodulin-származékok és azokat tartalmazó gyógyszerészeti készítmények elhízás kezelésére | |
| EP2240022A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| SMT201400069B (it) | Formulazione farmaceutica | |
| HUE053113T2 (hu) | Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra | |
| EP2373681A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| DK2391349T3 (da) | Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater | |
| FR2959935B1 (fr) | Forme pharmaceutique orale alcoolo-resistante | |
| DK3045164T3 (da) | Vandige farmaceutiske sammensætninger, der indeholder borat-polyol-komplekser | |
| EP2419097A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| DK2420223T3 (da) | Vandige farmaceutiske sammensætninger med borat-polyol-komplekser | |
| BRPI0921654A2 (pt) | formulação farmacêutica | |
| HRP20170959T1 (hr) | Farmaceutska suspenzija | |
| DK2391351T3 (da) | Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater | |
| EA201200616A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
| BR112013014189A8 (pt) | composição farmacêutica, uso de um agente de potencialização e uso de uma composição | |
| BRPI1006953A2 (pt) | composição farmacêutica, e, uso de uma composição | |
| DK2193795T3 (da) | Latanoprostholdig vandig farmaceutisk sammensætning | |
| EP2306998A4 (en) | PHARMACEUTICAL FORMULATION |